Pharma Stocks
-
Billionaire Tom Steyer Admires This Pharma Stock
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Liquidia Corporation (NASDAQ:LQDA) ranks 1st on this…
Read More » -
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Ziihera Priority Review Milestone
Jazz Pharmaceuticals (JAZZ) is back in focus after US regulators accepted a priority review of its supplemental biologics application for…
Read More » -
Do Chugai Pharmaceutical’s (TSE:4519) Strong Q1 Earnings And New Stock Plan Reframe Its Incentives Story?
Chugai Pharmaceutical Co., Ltd. reported first-quarter 2026 results with sales of ¥291,577 million, revenue of ¥321,747 million, and net income…
Read More » -
AptarGroup (ATR) Margin Compression Challenges Bullish Pharma Growth Narrative In Q1 2026
AptarGroup (ATR) opened 2026 with Q1 revenue of US$982.9 million and basic EPS of US$1.13, while trailing twelve month revenue…
Read More » -
Organon (OGN)’s Investors React Strongly as Sun Pharma Bets Big on Specialty Drug Expansion
After surging 119.70% so far in April, Organon & Co. (NYSE:OGN) secures a spot on our list of the mid-cap…
Read More » -
MRNA shares: Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimates
Moderna Inc stocks today jumped big. MRNA shares in Nasdaq rose over six per cent in the pre-market on Friday.…
Read More » -
Rajesh Palviya of Axis Sec suggests Sun Pharma, Chennai Petro, Great Eastern Shipping shares to buy next week
Stock market news: Benchmark stock indices, Sensex and Nifty 50, finished almost 1% lower on Thursday as rising crude oil…
Read More » -
Phathom Pharmaceuticals (PHAT) Loss Compression Challenges Bearish Narratives After Q1 2026 Results
Q1 2026 earnings snapshot and recent momentum Phathom Pharmaceuticals (PHAT) has just reported its Q1 2026 numbers, with the most…
Read More » -
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of…
Read More » -
Is It Too Late To Reassess Amneal Pharmaceuticals (AMRX) After Its 65% One-Year Surge?
Some investors may be wondering if Amneal Pharmaceuticals at around US$12.80 is still reasonably priced after a strong run, or…
Read More »